Cargando…

Emerging therapeutic agents for advanced non-small cell lung cancer

Advanced non-small cell lung cancer (NSCLC) is the most common type of lung cancer, with a poor prognosis and no known cure. Survival time is often short because of limited treatment options. Recent advances in targeted therapy and immunotherapy have changed the landscape for the treatment of advanc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Ruqin, Manochakian, Rami, James, Lauren, Azzouqa, Abdel-Ghani, Shi, Huashan, Zhang, Yan, Zhao, Yujie, Zhou, Kexun, Lou, Yanyan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7245927/ https://www.ncbi.nlm.nih.gov/pubmed/32448366 http://dx.doi.org/10.1186/s13045-020-00881-7

Ejemplares similares

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Genomic landscape of lung adenocarcinomas in different races
por: Shi, Huashan, et al.
Publicado: (2022)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Targeted therapy in advanced non-small cell lung cancer: current advances and future trends
por: Majeed, Umair, et al.
Publicado: (2021)

Emerging Targeted Therapies in Advanced Non-Small-Cell Lung Cancer
por: Li, Shenduo, et al.
Publicado: (2023)

Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
por: Wiest, Nathaniel, et al.
Publicado: (2021)

Immunotherapy in Non-Small Cell Lung Cancer With Actionable Mutations Other Than EGFR
por: Seegobin, Karan, et al.
Publicado: (2021)

First Report of Management of Sequential Small Cell Transformation and ALK I1171T Mutation as Resistance Mechanisms in a Patient With ALK-EML4 Fused Non–Small Cell Lung Adenocarcinoma With a Novel Combination of Temozolomide and Lorlatinib: A Case Report
por: Majeed, Umair, et al.
Publicado: (2023)

Brief report: risk stratification following curative therapy for stage I NSCLC
por: Butts, Emily, et al.
Publicado: (2023)

Emerging therapeutic agents for lung cancer
por: Dholaria, Bhagirathbhai, et al.
Publicado: (2016)

Patients with high-grade alectinib-induced skin rash: How do we desensitize these patients? A case report and review of literature
por: Seegobin, Karan, et al.
Publicado: (2020)

Emerging Lung Cancer Therapeutic Targets Based on the Pathogenesis of Bone Metastases
por: Oyewumi, Moses O., et al.
Publicado: (2014)

The evolution of the diminishing role of extrapleural pneumonectomy in the surgical management of malignant pleural mesothelioma
por: Azzouqa, Abdel-Ghani, et al.
Publicado: (2016)

Crizotinib‐associated renal cyst development may be associated with prolonged progression‐free survival in patients with ALK‐positive non‐small‐cell lung cancer: Case report and review of the literature
por: Wiest, Nathaniel E., et al.
Publicado: (2021)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies
por: Soyano, Aixa E., et al.
Publicado: (2018)

Immunotherapies targeting stimulatory pathways and beyond
por: Marin-Acevedo, Julian A., et al.
Publicado: (2021)

Efficacy of gemcitabine in combination with nanoparticle albumin‐bound paclitaxel in the treatment of recurrent ovarian cancer: A retrospective single institution review
por: Kase, Adam M., et al.
Publicado: (2023)

A Case of Full Recovery from Prolonged Cardiac Arrest after Infusion with Paclitaxel and Pembrolizumab
por: Sh Ahmed, Omar, et al.
Publicado: (2022)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Myelodysplasia-related acute myeloid leukemia and acute promyelocytic leukemia: concomitant occurrence of two molecularly distinct diseases
por: Vanegas, Yenny Alejandra Moreno, et al.
Publicado: (2018)

Technological and Therapeutic Advances in Advanced Small Cell Lung Cancer
por: Lum, Caroline, et al.
Publicado: (2019)

Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective
por: Zhou, Kexun, et al.
Publicado: (2023)

Mechanisms of drug resistance to immune checkpoint inhibitors in non-small cell lung cancer
por: Zhou, Kexun, et al.
Publicado: (2023)

Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
por: Athar, Teeba, et al.
Publicado: (2021)

Integratively Genomic Analysis Reveals the Prognostic and Immunological Characteristics of Pyroptosis and Ferroptosis in Pancreatic Cancer for Precision Immunotherapy
por: Yu, Ting, et al.
Publicado: (2022)

Screening for Potential Therapeutic Agents for Non-Small Cell Lung Cancer by Targeting Ferroptosis
por: Zhao, Xin, et al.
Publicado: (2022)

Identification pyroptosis-related gene signature to predict prognosis and associated regulation axis in colon cancer
por: Zhou, Kexun, et al.
Publicado: (2022)

Case Report: Termination of unplanned pregnancy led to rapid deterioration of non-small-cell lung cancer during osimertinib treatment
por: Ma, Qizhi, et al.
Publicado: (2023)

Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017)

Emerging therapeutic agents for genitourinary cancers
por: Zarrabi, Kevin, et al.
Publicado: (2019)

Emerging Therapeutic Agents for Colorectal Cancer
por: Nalli, Marianna, et al.
Publicado: (2021)

Advances and Therapeutic Perspectives in Extended-Stage Small-Cell Lung Cancer
por: Pierret, Thomas, et al.
Publicado: (2020)

Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer
por: Ulahannan, Susanna V, et al.
Publicado: (2011)

Antimicrobial Peptides: An Emerging Category of Therapeutic Agents
por: Mahlapuu, Margit, et al.
Publicado: (2016)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Important Flavonoids and Their Role as a Therapeutic Agent
por: Ullah, Asad, et al.
Publicado: (2020)

Discovery of Small Molecule NSC290956 as a Therapeutic Agent for KRas Mutant Non-Small-Cell Lung Cancer
por: Zhang, Jiaxin, et al.
Publicado: (2022)

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
por: Xiang, Yan, et al.
Publicado: (2022)

Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers
por: Russano, Marco, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_e8ju6l46qn4avccuqpdih74gb4